Genocea Biosciences (GNCA) presented some outstanding immunogenicity data at the American Society for Clinical Oncology ((ASCO)) 2019 medical meeting. It highlighted initial data from its phase 1/2a study using its neoantigen vaccine GEN-009. While this was just immunogenicity data, it was quite promising. Especially because it sets up for another potential catalyst in 2020. In order to diversify its neoantigen platform, the biotech is even advancing a neoantigen T-cell therapy known as GEN-011. This should act as a backup product, along with another neoantigen vaccine known as GEN-010.